Skip to content

‘Please Don’t:’ Analysts Scorn Unilever’s Takeover Ambitions

  • “This is a very bad deal,” writes analyst at Bernstein
  • Unilever shares plunge 7%, biggest drop in almost two years
A production line inside the Unilever NV factory in Rotterdam, Netherlands.

A production line inside the Unilever NV factory in Rotterdam, Netherlands.

Photographer: Jasper Juinen/Bloomberg

Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.

Analysts are denouncing Unilever Plc’s 50 billion pound ($68 billion) offer for GlaxoSmithKline Plc’s consumer health business in unusually strong words.